Welcome to EpilepsyU.com a social network dedicated to the epilepsy community

Share This Post

Childhood Epilepsy / Education / Epilepsy / Local / Media / Medicine / Neurology / News / Parents / Research / Seizures / Social Media / Technology / Treatment

FDA Approves Aptiom Anti-Seizure Drug For Epilepsy

FDA Approves Aptiom Anti-Seizure Drug For Epilepsy

AptiomThe U.S. Food and Drug Administration approved eslicarbazepine acetate, branded as Aptiom, as an add-on medication to reduce the frequency of partial seizures associated with epilepsy, the agency announced Friday. The drug is manufactured by Sunovion Pharmaceuticals in Marlborough, Mass.

According to the Centers for Disease Control and Prevention, each year there are 150,000 new cases of epilepsy, the neurological condition of recurring seizures. Seizures are episodes of abnormal electrical activity in the brain marked by generalized convulsions, unusual behavior, or repetitive limb movements, sometimes with loss of consciousness. Around 2.3 million people in the United States live with epilepsy. Partial seizures, a subtype of seizures which affect only part of the brain, make up the majority of new diagnoses of epilepsy. Although it is relatively uncommon, seizures could result in death.

Aptiom was shown to reduce the frequency of seizures in three randomized control trials testing the drug against a placebo. Participating subjects continued to use their previous anti-epileptic medications throughout the trials.

“Some patients with epilepsy do not achieve satisfactory seizure control from existing treatments,” said Dr. Eric Bastings, acting director of the Division of Neurology Products in the FDA. “It is important we continue to make new treatment options available to patients.”

The most common side effects experienced by trial subjects include dizziness, drowsiness, nausea, headache, double-vision, vomiting, fatigue, and loss of coordination. The FDA noted that taking esclicarbazepine acetate may cause suicidal thoughts or actions in a small number of people. The agency warns that anyone taking the drug who experiences unusual changes in mood — particularly worsening anxiety, depression, or thoughts about suicide — should contact their healthcare provider right away.

Share This Post

4 Comments

  1. May I ask the progression in the study of canabidiol?

    Reply
  2. Exactly progression with Canabidiol!!!
    No more PHARMA MEDS!!!

    Reply
  3. Renee H Ayoub, Kristi Leigh Walters – The FDA has approved clinical trials for Cannabidiol and they are in progress.

    You can easily expect years to pass before the same could be said for CBD. That is just the nature of clinical trials and new drug submissions to FDA for approved treatment of medical conditions. It is indeed sad that something potentially life-saving could take that long to reach market, but asking “are we there yet” doesn’t speed it up.

    Aptiom is very similar to other drugs already used as AEDs, and still took years to reach the point of FDA approval for sale as an on-label, add-on treatment for Epilepsy.

    We feel honored that you think we have any control over the advancement of this process for CBD, but unfortunately we do not. We also have no stake in any pharmaceutical manufacturer or distributor and are not sharing the news about new medicines like this one with any sort of agenda. Simply sharing the news about new treatment options.

    And no, we are not there yet 🙂

    Reply
  4. Ty so for your quick redponse. My daughter is an adult onset case and trials of meds later she is @ toxic level of keppra so my concern is high. Again ty.

    Reply

Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>

Lost Password

Register